Zurich: Novel compounds to treat severe inflammation and ischaemia-reperfusion events

Licensing opportunity

Researchers at University Hospital Zurich and ETH-Zurich, Switzerland, have identified novel injectable, water-soluble compounds which are particularly suitable for treating or protecting patients suffering from a severe inflammation or an ischaemia-reperfusion event. Unlike currently used volatile anaesthetics, they say, no cost-intensive monitoring during the application is required.

Severe inflammatory syndromes are found in sepsis, acute lung inuries and life-threatening asthma, among other conditions. Ischemia-reperfusion events occur in, for example,aortic aneurysm repair, multiple trauma, peripheral vascular disease, renal vascular disease, myocardial infarction, instable angina, stroke, impending stroke and transient ischemic attacks. The new compounds can also protect organ during surgical interventions.

A patent has been filed, and is now available for licensing.